All Posts Tagged With: "SRDX"
(SRDX) SurModics Analyst Moves Shares Up to Outperform
We recently upgraded SurModics Inc. (SRDX) to Outperform from Neutral following its impressive results in the third quarter of fiscal 2012 (ended June 30, 2012). The stock carries a Zacks #2 Rank (Buy rating) in the short run. SurModics’...21Aug2012 | vitalstocks | Comments Off | Continued
(SRDX) SurModics Analysts Cut Shares to Neutral
We are downgrading SurModics (SRDX) to Neutral from Outperform following its setback, when partner Johnson & Johnson (JNJ) announced in June 2011 that it will...10Jul2011 | vitalstocks | 0 comments | Continued
(SRDX) SurModics Incorporated – Bull of the Day
In June 2011, SurModics, Inc. (SRDX) received a blow when Johnson & Johnson announced that it will stop manufacturing Cypher stents by year end, as SurModics receives royalties on sales of the product. However, we believe the...21Jun2011 | vitalstocks | 0 comments | Continued
(SRDX) SurModics Analyst Increases Shares to Outperform
We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Our target price on the stock is $18.00. The company delivered strong results in the second...4May2011 | vitalstocks | 0 comments | Continued
(SRDX) SurModics Incorporated – Bull of the Day
We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Adjusted earnings in the quarter came in at $0.08 per share, well ahead of break-even earnings suggested...4May2011 | vitalstocks | 0 comments | Continued
(SRDX) SurModics Analyst Maintains Neutral Rating on Shares
SurModics (SRDX), headquartered in Eden Prairie, Minnesota, is a provider of surface modification and drug delivery technologies to the healthcare industry. Following the changes in operational structure affected in 2008, the...14Sep2010 | vitalstocks | 0 comments | Continued
(SRDX) SurModics Signs Deal With Australian company Clinuvel Pharmaceuticals
Recently, SurModics Inc. (SRDX) inked a licensing deal with Australian company Clinuvel Pharmaceuticals Limited. The deal allows SurModics’ pharmaceuticals unit, which provides proprietary polymer-based drug delivery technologies...11Jul2010 | vitalstocks | 0 comments | Continued
(SRDX) SurModics Analysts Upgrades the Stock to Neutral
We have recently upgraded our recommendation on SurModics (SRDX) to Neutral. During the first quarter of 2010, the company’s earnings per share (EPS) came in at 24 cents, surpassing the Zacks Consensus Estimate by 5 cents. Although...27Mar2010 | vitalstocks | 0 comments | Continued
(SRDX) SurModics Earnings Report Beats Expectations
SurModics (SRDX) reported first quarter fiscal 2010 earnings per share (EPS) of 11 cents, down from $1.53 in the year ago period. However, after adjustments, the EPS of 24 cents surpassed the Zacks Consensus Estimate by 5 cents. The...29Jan2010 | vitalstocks | 0 comments | Continued
(SRDX) SurModics Misses Earnings Estimates
SurModics’ (SRDX) fourth-quarter earnings per share came in at 18 cents, below the Zacks Consensus Estimate of 20 cents. The company reported revenues of $19.2 million, down 17% compared to the year...7Nov2009 | vitalstocks | 0 comments | Continued
(SRDX) Surmodics Inks Licensing Deal With Roche
On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use...9Oct2009 | vitalstocks | 0 comments | Continued
(MYGN) Biotech Industry – Zacks Analyst Interviews
OVERVIEW The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes...1Jun2009 | vitalstocks | 0 comments | Continued
(WYE) Biotech Industry – Industry Outlook
OVERVIEW The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009. Large biotech companies are doing OK since they have strong balance sheets...13Mar2009 | vitalstocks | 0 comments | Continued